Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2008

View Archived Issues

Mutations behind Duane's retraction syndrome identified

Background data on CR-845 presented during recent World Congress on Pain

Preliminary phase II results show pain relief with XEN-2127 in oncology patients

Terlipressin benefits patients awaiting liver transplant with renal failure, hyponatremia

ALK-Abello reports positive results from phase II/III of allergy vaccine against dust mites

Rosetta enters collaboration with NIH to identify microRNAs involved in HIV viral replication

Pipex acquires AT-001 for rheumatoid arthritis

DelSite files IND with the FDA for phase I safety and immunogenicity study of GelVac

New therapeutic agents for obesity described in recent patents

Recent patent literature discloses new anticancer agents

New treatment options for osteoporosis disclosed in recent Novartis patent

V-2006 development for Parkinson's disease advances

Biovex receives regulatory clearance to begin studies with ImmunoVEX-HSV2

PolyMedix commences dosing in phase I novel systemic antibiotic trial

Repros reports no tumors in completed Proellex animal carcinogenicity study

Vidaza receives expanded FDA approval in high-risk MDS patients

Metvix prevents precancerous lesions in transplant patients

Ardea Biosciences commences phase I trials for gout candidate RDEA-594

Cymbalta approved in Europe for the treatment of generalized anxiety disorder

FDA fast tracks ferumoxytol for vascular-enhanced magnetic resonance imaging

Phase III trial commences for Nexavar as adjuvant therapy in liver cancer

Auris Medical reports results of phase I/II AM-101 trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...